Technology ID
TAB-3518
Remodelins, a New Class of Compounds to Prevent Airway Remodeling and to Treat and Prevent Fibrosis in Multiple Organs
E-Numbers
E-120-2018-0
Lead Inventor
Luci, Diane (NCATS)
Co-Inventors
Maloney, David (NCATS)
Applications
Therapeutics
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NCATS
ICs
NCATS
This technology includes a new class of compounds, called remodelins, which can be used to prevent airway remodeling and prevent lung fibrosis. Currently no effective therapies are available for lung fibrosis. This compound could also be employed as a treatment for asthma.
Commercial Applications
Further clinical work with the remodelins could establish them as a treatment =for lung fibrosis and asthma.
Competitive Advantages
There are currently no therapies available for lung fibrosis and no asthma treatments are specifically targeted against airway remodelin.
Licensing Contact: